Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Status:
Enrolling by invitation
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether once-daily dosing of patiromer will reduce
the frequency of hyperkalemic episodes in ESRD (end stage renal disease) study participants
who receive conventional hemodialysis (HD). The study objective is to determine if patiromer
administered orally once a day with breakfast or lunch will reduce episodes of hyperkalemia
in ESRD study participants who receive thrice-weekly HD.